Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 7. Annual reported cases of notifiable diseases and rates, by ethnicity*,†, United States, excluding U.S. Territories and Non-U.S. Residents, 2022
Disease Hispanic or Latino Non-Hispanic/Latino Ethnicity not stated Total
No. Rate No. Rate No. No.
Anthrax — — — — — —
Arboviral diseases
Chikungunya virus disease 18 0.03 43 0.02 20 81
Eastern equine encephalitis virus disease
Neuroinvasive S S S S S 1
Non-neuroinvasive — — — — — —
Jamestown Canyon virus disease
Neuroinvasive S S S S S 11
Non-neuroinvasive S S S S S 1
La Crosse virus disease
Neuroinvasive S S S S S 19
Non-neuroinvasive S S S S S 3
Powassan virus disease
Neuroinvasive — — 38 0.01 4 42
Non-neuroinvasive S S S S S 4
St. Louis encephalitis virus disease
Neuroinvasive 6 0.01 15 0.01 7 28
Non-neuroinvasive S S S S S 6
West Nile virus disease
Neuroinvasive 106 0.17 549 0.20 173 828
Non-neuroinvasive 25 0.04 190 0.07 95 310
Western equine encephalitis virus disease
Neuroinvasive — — — — — —
Non-neuroinvasive — — — — — —
Babesiosis
Total 145 0.25 1,212 0.53 754 2,111
Confirmed 127 0.22 1,034 0.45 651 1,812
Probable 18 0.03 178 0.08 103 299
Botulism
Total 50 0.08 109 0.04 38 197
Foodborne S S S S S 6
Infant 39 3.91 92 3.43 32 163
Other (wound & unspecified) 10 0.02 13 0.00 5 28
Brucellosis 67 0.11 35 0.01 24 126
Campylobacteriosis 9,195 14.44 39,536 14.66 17,882 66,613
Candida auris, clinical § 85 0.20 735 0.33 181 1,001
Carbapenemase-producing carbapenem-resistant Enterobacteriaceae 213 0.50 1,547 0.71 1,058 2,818
Chancroid S S S S S 1
Chlamydia trachomatis infection  234,269 367.98 786,443 291.68 628,872 1,649,584
Cholera S S S S S 12
Coccidioidomycosis 3,181 11.85 7,219 6.33 7,212 17,612
Coronavirus Disease 2019 (COVID-19)
Total 6,676,290 10,486.70 24,704,286 9,162.52 11,752,219 43,132,795
Confirmed 5,535,530 8,694.87 19,414,528 7,200.61 9,327,346 34,277,404
Probable ** 1,140,760 1,791.83 5,289,758 1,961.91 2,424,873 8,855,391
Cryptosporidiosis
Total 1,374 2.16 8,300 3.08 2,932 12,606
Confirmed 1,155 1.81 6,489 2.41 2,525 10,169
Probable 219 0.34 1,811 0.67 407 2,437
Cyclosporiasis 466 0.77 1,717 0.69 908 3,091
Dengue virus infections ††
Dengue 1,062 1.67 291 0.11 101 1,454
Dengue-like illness 22 0.03 9 0.00 2 33
Severe dengue 31 0.05 12 0.00 — 43
Diphtheria S S S S S 1
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 71 0.12 3,819 1.47 1,761 5,651
Ehrlichia chaffeensis infection 40 0.07 1,211 0.47 318 1,569
Ehrlichia ewingii infection 1 0.00 23 0.01 1 25
Undetermined ehrlichiosis/anaplasmosis 2 0.00 75 0.03 18 95
Giardiasis 1,507 3.20 7,052 3.23 5,260 13,819
Gonorrhea 83,854 131.71 373,211 138.42 190,945 648,010
Haemophilus influenzae, invasive disease
All ages, all serotypes 422 0.66 4,072 1.51 842 5,336
Age <5 years
Serotype b S S S S S 17
Non-b serotype 6 0.12 100 0.73 34 140
Nontypeable 51 1.04 156 1.14 47 254
Unknown serotype 36 0.06 181 0.07 56 273
Hansen's disease 9 0.02 35 0.01 18 62
Hantavirus infection, non-hantavirus pulmonary syndrome §§ — — — — — —
Hantavirus pulmonary syndrome S S S S S 11
Hemolytic uremic syndrome post-diarrheal 40 0.07 239 0.10 33 312
Hepatitis, Viral Disease ¶¶
Hepatitis A 387 0.61 1,664 0.62 213 2,264
Hepatitis B
Acute 258 0.41 1,614 0.60 254 2,126
Perinatal infection S — S — S 13
Hepatitis C
Acute 653 1.07 3,922 1.49 1,053 5,628
Confirmed 582 0.95 3,329 1.26 937 4,848
Probable 71 0.12 593 0.22 116 780
Perinatal infection 11 NC 124 NC 62 197
Human immunodeficiency virus diagnoses 11,814 18.56 25,849 9.59 — 37,663
Influenza-associated pediatric mortality 25 0.13 77 0.14 14 116
Invasive pneumococcal disease ***
All ages 1,676 4.01 13,612 6.55 3,074 18,362
Confirmed 1,634 3.91 13,303 6.40 2,979 17,916
Probable 42 0.10 309 0.15 95 446
Age <5 years 191 0.43 785 0.35 141 1,117
Confirmed 186 5.25 757 6.61 135 1,078
Probable 5 0.14 28 0.24 6 39
Legionellosis 558 0.88 5,716 2.12 1,238 7,512
Leptospirosis 3 0.01 37 0.02 22 62
Listeriosis †††
Total 142 0.22 708 0.26 113 963
Confirmed 129 0.20 668 0.25 105 902
Probable 13 0.02 40 0.01 8 61
Lyme disease §§§
Total 1,171 1.84 26,077 9.72 35,180 62,428
Confirmed 44 0.07 1,389 0.52 633 2,066
Probable 1,127 1.77 24,688 9.20 34,547 60,362
Malaria 81 0.13 1,377 0.52 474 1,932
Measles ¶¶¶
Total 3 0.00 110 0.04 8 121
Indigenous 3 0.00 87 0.03 8 98
Imported — — 23 0.01 — 23
Meningococcal disease
All serogroups 74 0.12 225 0.08 13 312
Serogroups ACWY 56 0.09 105 0.04 7 168
Serogroup B 7 0.01 39 0.01 1 47
Other serogroups 2 0.00 18 0.01 — 20
Unknown serogroup 9 0.01 63 0.02 5 77
Mpox **** 8,633 13.56 18,348 6.81 2,840 29,821
Mumps 77 0.12 229 0.08 80 386
Novel Influenza A virus infections S S S S S 12
Pertussis 438 0.69 2,018 0.75 588 3,044
Plague †††† — — — — — —
Poliomyelitis, paralytic S S S S S 1
Poliovirus infection, nonparalytic — — — — — —
Psittacosis S S S S S 7
Q fever
Total 36 0.06 114 0.04 44 194
Acute 33 0.05 101 0.04 37 171
Chronic 3 0.00 13 0.00 7 23
Rabies
Human — — — — — —
Rubella S S S S S 7
Rubella, congenital syndrome — — — — — —
Salmonella Paratyphi infection §§§§ 12 0.02 91 0.03 27 130
Salmonella Typhi infection ¶¶¶¶ 73 0.11 260 0.10 109 442
Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ***** 9,235 14.51 32,923 12.21 13,971 56,129
Severe acute respiratory syndrome-associated coronavirus disease — — — — — —
Shiga toxin-producing Escherichia coli (STEC) 3,123 4.91 9,932 3.68 3,351 16,406
Shigellosis 3,586 5.63 7,551 2.80 3,607 14,744
Smallpox — — — — — —
Spotted fever rickettsiosis
Total 41 0.06 908 0.34 343 1,292
Confirmed 5 0.01 33 0.01 9 47
Probable 36 0.06 875 0.33 334 1,245
Streptococcal toxic shock syndrome 13 0.05 256 0.14 64 333
Syphilis
Total, all stages ††††† 52,629 82.67 131,675 48.84 22,919 207,223
Congenital §§§§§ 1,099 123.98 2,502 88.56 154 3,755
Primary and secondary 11,831 18.58 41,528 15.40 5,651 59,010
Tetanus 3 0.00 22 0.01 1 26
Toxic shock syndrome (other than Streptococcal) 1 0.00 12 0.01 18 31
Trichinellosis S S S S S 9
Tuberculosis 2,824 4.44 5,430 2.01 77 8,331
Tularemia 7 0.01 133 0.05 27 167
Vancomycin-intermediate Staphylococcus aureus 4 0.01 61 0.03 17 82
Vancomycin-resistant Staphylococcus aureus ¶¶¶¶¶ S S S S S 2
Varicella morbidity 856 1.53 2,447 1.10 1,045 4,348
Varicella mortality U U U U U U
Vibriosis
Total 420 0.66 1,887 0.71 731 3,038
Confirmed 199 0.31 957 0.36 318 1,474
Probable 221 0.35 930 0.35 413 1,564
Viral hemorrhagic fevers
Chapare virus ****** — — — — — —
Crimean-Congo hemorrhagic fever virus †††††† — — — — — —
Ebola virus †††††† — — — — — —
Guanarito virus †††††† — — — — — —
Junin virus †††††† — — — — — —
Lassa virus †††††† — — — — — —
Lujo virus †††††† — — — — — —
Machupo virus †††††† — — — — — —
Marburg virus †††††† — — — — — —
Sabia virus †††††† — — — — — —
Yellow fever — — — — — —
Zika virus
Zika virus disease, congenital §§§§§§ S S S S S 1
Zika virus disease, non-congenital S S S S S 5
Zika virus infection, congenital §§§§§§ — — — — — —
Zika virus infection, non-congenital S S S S S 2
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • NC: Not Calculated — There is insufficient data available to support this statistic.
  • U: Unavailable — The data are unavailable.
  • S: Suppressed
  • * Conditions with <25 cases reported in the year were not broken down by ethnicity.
  • † Any variation of disease incidence by race or ethnicity does not reflect biological differences but reflects systemic, cultural, behavioral, and social factors including structural racism.
  • § Note that Candida auris colonization/screening cases are not included in this table. Additionally, there may be case count discrepancies of Candida auris clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for Candida auris case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
  • ¶ Beginning in January 2022, only confirmed cases are published to align with the approved CSTE position statement 21-ID-06, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.
  • ** Of the reporting areas that submitted 2022 aggregate COVID-19 data to CDC, three did not submit probable cases. American Samoa, New York (excluding New York City), and U.S. Virgin Islands did not collect probable cases.
  • †† Counts include confirmed and probable dengue cases.
  • §§ Case counts may include Old World hantavirus infections, such as Seoul virus.
  • ¶¶ Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2022, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • *** Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • ††† Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately.
  • §§§ For surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Confirmed cases are only reported from low-incidence jurisdictions; however, probable cases are reported from both high- and low-incidence jurisdictions. For more information on jurisdiction classifications, visit https://www.cdc.gov/lyme. Currently, high-incidence jurisdictions include Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York (excluding New York City), New York City, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin, and the District of Columbia.
  • ¶¶¶ Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
  • **** CSTE adopted Mpox as a nationally notifiable condition on June 23, 2022 and beginning August 1, 2022 confirmed and probable cases are published to align with the CSTE position statement 22-ID-10. Case classifications for cases reported prior to August 1, 2022 should not have been retroactively changed based on the case definition in the CSTE position statement 22-ID-10.
  • †††† Beginning in 2020, confirmed and probable plague cases began to be combined and published.
  • §§§§ Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • ¶¶¶¶ Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever.
  • ***** Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • ††††† Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis.
  • §§§§§ Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth.
  • ¶¶¶¶¶ Vancomycin-resistant Staphylococcus aureus cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant Staphylococcus aureus cases in 2022.
  • ****** Beginning in January 2022, Chapare virus was added as a nationally notifiable condition, and confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04.
  • †††††† Beginning in January 2022, confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04, whereas in previous years, only confirmed cases were published.
  • §§§§§§ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
  • Delaware identified an issue preventing the correct assignment of ethnicity values within their surveillance system for a portion of the conditions included in the 2022 NNDSS Annual Tables. Cases of hepatitis, human immunodeficiency virus diagnoses, sexually transmitted diseases, and tuberculosis were not impacted, but Delaware's case counts for all other conditions were re-assigned to 'Ethnicity not stated' in Table 7.
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024.
  2. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/. For more information, see https://seer.cancer.gov/popdata/singleages.html Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports".
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction is ≤24 months)
    • Perinatal hepatitis C infection (age restriction is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.